petrodollar as masculine, med-dollar as feminine
The Currency You Can't See: Petrodollars, Med-Dollars, and the Power That Enters Your Bloodstream
by Anushka
I want to tell you about a framework I built in my head — and then had to partially dismantle. Not because it was wrong, but because reality turned out to be stranger, and in some ways more unsettling, than my original intuition.
It started with a simple observation: that the petrodollar and what I was beginning to think of as the "med-dollar" are not just different economic systems. They are different aesthetics of power. Different grammars. Different genders, if you want to push the metaphor — and I did want to push it, because I think it's the most useful way to understand what's actually happening to global hegemony right now.
Let me explain what I mean.
The Petrodollar Is Loud. That's the Point.
The petrodollar system — formalized through the 1974 Kissinger-Saudi deal, which effectively made oil trade dollar-denominated in exchange for American military guarantees — has always operated through announcement. It is a system of visible force. Aircraft carriers. Sanctions. "America First." Tariffs as theater. Trump's entire foreign policy grammar is legible precisely because it operates in this register: it announces itself, it demands acknowledgment, it needs you to know who is in charge.
This is what I mean by masculine aesthetics of power. Not masculine in a biological sense, but in the structural sense: it operates through declaration, through presence, through the logic of the battlefield. You either comply or face consequences you can see coming.
The genius of the petrodollar — and its vulnerability — is that it is nameable. BRICS exists because countries could identify, point to, and collectively resist a visible system of dominance. De-dollarization is a geopolitical movement precisely because people know what they are moving away from. You cannot organize resistance against something you cannot name.
Which brings me to what I've started calling the med-dollar.
The Med-Dollar Doesn't Knock. It's Already Inside.
When I first conceived of this framework, I was thinking about the growing financialization of health — the way that biological processes, bodies, illness, and longevity have become the new frontier of capital accumulation. The petrodollar colonized geography. The med-dollar colonizes metabolism.
But my original framing was too neat. I imagined it as a kind of scheming, invisible counterpart to the petrodollar's brazenness — more pervasive precisely because it doesn't announce itself. And that much is true. What I underestimated was the mechanism.
I went looking for evidence of pharma companies directly investing in junk food companies — the most obvious version of the conflict of interest I was sensing. And while that specific link is harder to prove directly, what I found instead was more structurally elegant and more disturbing: the common ownership problem.
BlackRock, Vanguard, and State Street — three asset management giants — collectively own somewhere around 20% of total US market capitalisation, and hold roughly 25% of voting shares across S&P 500 companies. They are the largest shareholders in 88% of those companies. What this means in practice is that the same institutional owners sit atop both the companies that manufacture ultra-processed food and the companies that profit from treating the resulting metabolic disease.
They don't need to conspire. The incentive structure does it for them. When the same capital pool benefits from illness-generating and illness-treating industries simultaneously, you have a closed loop that requires no boardroom plot, no villain twirling a mustache. It is systemic. It is architectural. And it is, almost by definition, invisible — because the mechanism is ownership, not action.
This is the med-dollar. It doesn't threaten borders. It invests in both sides of your body's relationship with itself.
The Tobacco Prototype: This Has Happened Before
This isn't entirely new territory. There's a documented historical precedent in the relationship between pharmaceutical and tobacco companies — one that served as a prototype for exactly this kind of closed-loop capital logic.
Corporate diversification allowed for well-hidden financial ties between pharma and tobacco that generated genuine conflicts of interest: cases where tobacco companies pressured pharmaceutical partners to scale back smoking cessation educational materials. The same capital, benefiting from addiction and from the drugs that treat addiction's consequences.
And now look at where tobacco companies have gone. Philip Morris International now owns inhaler devices, respiratory products, and oral nicotine alternatives. British American Tobacco has subsidiaries working on vaccines and cannabis. Japan Tobacco International has a pharmaceutical division. The companies that spent a century making people sick have quietly become the companies trying to make them well — or at least, making them dependent on new products that sit in the wellness register.
This is the med-dollar's genealogy. Illness as asset class. Health as market. Bodies as the new geography to be colonized.
The WHO Exit: What I Thought It Meant, and What It Actually Did
Now, here is where I have to make a correction — and I want to make it clearly, because intellectual honesty is the only standard worth holding yourself to.
When Trump withdrew from the WHO in January 2025, on his first day back in office, my initial instinct was to read it as a crack in the system — that removing the institutional gatekeeper might free up alternative research pipelines, allow suppressed discoveries to surface, let science breathe outside the apparatus.
And to be fair, 2025 has been a remarkable year for cancer research: CRISPR-edited tumor-infiltrating lymphocytes showing early results, personalized neoantigen vaccines training the immune system to recognize unique tumor fingerprints, allogeneic CAR-T therapies advancing through trials. The headlines have been genuinely exciting.
But here is the correction: these breakthroughs were not caused by the WHO exit. They were in development pipelines for years — funded by pre-existing NIH grants, EU Horizon programs, UK Cancer Research, and private biotech investment. The timeline doesn't support the liberation narrative. If anything, the US withdrawal created disruption, not discovery.
What the data actually shows is this: the federal government cut approximately $2.7 billion in NIH funding in the first three months of 2025, including a 31% decrease in cancer research funding compared to the same period the previous year. The NIH awarded 24% fewer grants and 19% less grant money for cancer research. More than 380 clinical trials were interrupted — over 115 of them cancer-focused. Trump's proposed 2026 NCI budget represents a 37.3% decrease from 2025 levels.
So the breakthroughs happened in spite of the institutional disruption, not because of it. And crucially, the European and Asian research pipelines — already active, already well-funded — are now accelerating to fill the vacuum left by American withdrawal. The irony my framework anticipated is real, but inverted: what's being freed from American gatekeeping is not American science, but everyone else's.
Diversification Is De-Dollarization in a Suit
Here is the thread that still holds, and holds even more firmly after the corrections.
In financial and policy discourse, "portfolio diversification" is an acceptable term. "De-dollarization" triggers alarm — it implies a geopolitical challenge to American hegemony, it sounds confrontational, it invites retaliation. And yet, if every sovereign wealth fund is quietly shifting significant portions of their allocation into health infrastructure, biotech, longevity research, and medical supply chains — that is, structurally, a currency shift in slow motion.
The currency just happens to be biological dependency rather than petro-receipts.
This linguistic substitution is itself an example of the med-dollar's operating grammar. The petrodollar names its own power. The med-dollar speaks in the language of wellness, innovation, diversification, and portfolio management. It is fluent in the discourse of progress. It doesn't say "this is control." It says "this is an opportunity."
And this is why the med-dollar is harder to resist than the petrodollar. You can route around American oil pricing by trading in yuan. You cannot route around BlackRock by switching currencies, because BlackRock's positions aren't tied to a currency — they're tied to ownership itself.
The Protein Condom and the Biologization of Commerce
I want to end with an example that might seem absurd but is actually a perfect symptom of the trend I've been tracing: the emergence of protein-based "biopolymer" condom technology from pharmaceutical and materials science research pipelines.
When medical analytics starts producing innovations that merge everyday bodily products with pharmaceutical-grade materials and the data infrastructure that surrounds them, you are witnessing what I would call the biologization of commerce — the penetration of the medical-capital apparatus into the most intimate corners of ordinary life. It is strange. It is also entirely logical given the architecture we've been mapping.
This is not a conspiracy theory. It is a structural observation. Capital follows the body. The body is the last market.
What I Actually Believe Now
I started with a metaphor — petrodollar as masculine, med-dollar as feminine. I still think the metaphor is useful, but I want to be precise about what it describes.
It's not about gender in any biological or social sense. It's about visibility as a feature of power. The petrodollar's power is visible by design — it works through deterrence, which requires being seen. The med-dollar's power is invisible by design — it works through ownership and dependency, which function best when unexamined.
Both are real. Both are operating simultaneously. And the transition between them — the slow shift of global capital from extracting resources from the ground to extracting value from human biological processes — is one of the most significant structural changes of our era.
The tragedy of the WHO withdrawal moment is not that it freed science. It's that it clarified the ownership: when the American state stepped back, the institutional capital that funds research didn't go away. It just became more visibly stateless. And stateless capital, accountable to no government and no citizenry, is the med-dollar's purest form.
This is the currency you can't see. It doesn't petrol your car. It doesn't sanction your country. It just quietly holds positions in both your dinner and your doctor.
And it is not going anywhere.
Comments
Post a Comment